5′-,3′-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine

Takei, Yoshiyuki; Kadomatsu, Kenji; Itoh, Hiroshi; Sato, Waichi; Nakazawa, Kumiko; Kubota, Shunichiro; Muramatsu, Takashi

doi:10.1074/jbc.m112100200

Cited by 49 publications

(51 citation statements)

References 45 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These activities include transforming, migrating, fibrinolytic, mitogenic, antiapoptotic, and angiogenic ones (Kojima et al, 1995;Choudhuri et al, 1997;Kadomatsu et al, 1997;Qi et al, 2000Qi et al, , 2001. Furthermore, we recently succeeded in suppressing tumour growth by using antisense MK oligodeoxyribonucleotide (Takei et al, 2001(Takei et al, , 2002. Thus, ablation of MK production or disruption of its signalling pathway could be a strong means of curing neuroblastomas.…”

Section: Discussionmentioning

confidence: 99%

“…MK transforms NIH3T3 cells , enhances fibrinolysis (Kojima et al, 1995), and promotes cell growth (Muramatsu and Muramatsu, 1991;Muramatsu et al, 1993;Takei et al, 2001), cell survival (Qi et al, 2000), cell migration (Takada et al, 1997;Maeda et al, 1999;Horiba et al, 2000;Qi et al, 2001), and angiogenesis (Choudhuri et al, 1997). MK antisense oligodeoxyribonucleotide suppresses tumour progression in nude mice (Takei et al, 2001(Takei et al, , 2002.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas

et al. 2003

View full text Add to dashboard Cite

The heparin-binding growth factor midkine (MK) is the product of a retinoic acid-responsive gene, and is implicated in neuronal survival and differentiation, and carcinogenesis. We previously reported that MK mRNA expression is elevated in neuroblastoma specimens at all stages, whereas pleiotrophin, the other member of the MK family, is expressed at high levels in favourable neuroblastomas. As MK is a secretory protein, it can be detected in the blood. Here, we show a significant correlation of the plasma MK level with prognostic factors of neuroblastomas. The plasma MK level was determined in 220 patients with neuroblastomas, and compared with that in children without malignant tumors (n ¼ 17, o500 pg ml À1 ). The plasma MK level became significantly elevated with advancing stages (stage 1: 445 pg ml À1 (median), n ¼ 73; stage 2: 589, n ¼ 39; stage 3: 864, n ¼ 40; stage 4: 1445, n ¼ 56; and stage 4S: 2439, n ¼ 12). More importantly, a higher MK level was strongly correlated with poor prognostic factors: over 1 year of age (P ¼ 0.0299), MYCN amplification (Po0.0001), low TrkA expression (P ¼ 0.0005), nonmass screening, sporadic neuroblastomas (Po0.0001), and diploidy/tetraploidy (P ¼ 0.0007). Thus, these results demonstrate that the plasma MK level is a good marker for evaluating the progression of neuroblastomas. Moreover, considering the ability of antisense MK oligodeoxyribonucleotide to suppress tumour growth of colorectal carcinoma cells in nude mice, as recently reported, the present study suggests that MK is a possible candidate molecular target for therapy for neuroblastomas.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas

et al. 2003

View full text Add to dashboard Cite

show abstract

“…(13,14) MK is barely detectable in normal adult tissues. Furthermore, the present study has established that high blood MK level is closely related to poor prognosis, at least in NBL.…”

Section: Discussionmentioning

confidence: 99%

“…(11,12) Knockdown of MK expression leads to suppression of xenografted tumors of mouse colorectal cancer cells and human prostate cancer cells. (13,14) We previously reported that the plasma MK level was correlated with the values of established prognostic factors through a study of 220 cases, including 82 non-mass-screening (sporadic) cases and 122 mass-screening cases. (15) However, in that study, information on the prognosis of patients was too limited to determine whether the plasma MK level could be a prognostic factor.…”

mentioning

confidence: 99%

Plasma midkine level is a prognostic factor for human neuroblastoma

et al. 2008

Self Cite

View full text Add to dashboard Cite

Neuroblastoma is the third-most-common solid tumor of childhood. To date, no reliable blood marker for neuroblastoma has been established. The growth factor midkine is highly expressed in human carcinomas and its knockdown leads to tumor growth suppression in animal models. The present study evaluated the plasma midkine level in human neuroblastoma patients. Plasma samples were obtained from patients found through mass screening, as well as from sporadic neuroblastoma patients. The total number of cases examined was 756. Among them, prognostic information was available for 175 sporadic cases and 287 mass-screening cases. Midkine levels were significantly higher in neuroblastoma patients, including both mass-screening cases and sporadic cases, than in non-tumor controls (P < 0.0001). The midkine level was significantly correlated with the statuses of MYCN amplification, TRKA expression, ploidy, stage and age (P < 0.0001, < 0.0001, = 0.004, < 0.0001 and < 0.0001, respectively), which are known prognostic factors for neuroblastoma. There was a striking correlation between high plasma midkine level and poor prognosis (P < 0.0001). Within sporadic cases, the midkine level was also strikingly higher than in non-tumor controls (P < 0.0001), and correlated with the statuses of MYCN amplification and stage (P = 0.0005 and = 0.003, respectively). There was a significant correlation between high plasma midkine level and poor prognosis (P = 0.04). Taken N euroblastoma (NBL) is the third-most-common malignant tumor of childhood, accounting for 15% of cancer-related death. (1) In spite of an enormous amount of research devoted to curing this disease, its prognosis remains poor. NBL has several established prognostic factors, i.e. MYCN amplification, TRKA expression level, ploidy, stage and age. (1,2) Cases with tumors with an amplified MYCN gene, low TRKA expression or diploidy show poor prognosis. Cases at stage 3 or 4, or at ages older than 18 months also show poor prognosis. Since molecular fingerprints within tumor tissues, such as MYCN amplification, TRKA expression level and ploidy, require a tumor biopsy or its removal, a blood marker for NBL has long been awaited. (1,2) A blood marker would not only be useful for the initial diagnosis but would also be beneficial for the sequential monitoring of the tumor status.The growth factor midkine (MK) was originally found in embryonal carcinoma cells, and has been implicated in cancer development. (3)(4)(5) MK is highly and frequently expressed in human carcinomas, including Wilms' tumor, tumors of the digestive tract, brain tumors, urinary bladder tumors and breast tumors, whereas its expression is scarcely detected in normal adult tissues. (6-10) Strong MK expression is also detected in precancerous stages of human colorectal cancer and human prostate cancer. (11,12) Knockdown of MK expression leads to suppression of xenografted tumors of mouse colorectal cancer cells and human prostate cancer cells. (13,14) We previously reported that the plasma MK level was correlated wit...

show abstract

“…For calculation of the half-life of each siRNA in serum, all bands were analyzed with an imaging densitometer (GelDoc 1000 system, Bio-Rad) as reported previously (26).…”

Section: Northern Blot Analysismentioning

confidence: 99%

In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency

Takei

Nemoto²,

et al. 2008

Molecular Cancer Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

5′-,3′-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine

Cited by 49 publications

References 45 publications

Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas

Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas

Plasma midkine level is a prognostic factor for human neuroblastoma

In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency

Contact Info

Product

Resources

About